Standex's Q4 2025: Unpacking Contradictions in Capacity, Orders, and Acquisitions

Capacity utilization and expansion plans for Amram/Narayan, order growth and outlook for fiscal 2026, NIH funding impact on Scientific segment, and restructuring in Engraving are the key contradictions discussed in Standex International Corporation's latest 2025Q4 earnings call.



Revenue and Acquisition Impact:
- Standex International reported $222 million in consolidated revenue for Q4 2025, up 23.2% year-on-year.
- This growth was driven by contributions from recent acquisitions, particularly Amran/Narayan and McStarlite, which accounted for a 23.4% increase.

Adjusted Operating Margin Improvement:
- The company achieved a record adjusted operating margin of 20.6%, up 350 basis points year-on-year.
- This improvement was due to favorable product mix, pricing initiatives, and operational efficiencies, particularly in the Electronics segment.

Organic Growth and New Product Sales:
- Electronics segment saw 0.3% organic growth, marking the first quarter of organic increase since 2023.
- New product sales contributed approximately 2.8% to overall sales, surpassing the goal of 2% and highlighting the impact of increased R&D spending.

Fast Growth Market Sales Expansion:
- Sales into fast growth markets rose to 28% of total company sales in Q4 2025.
- This growth was driven by increased demand in electrical grid modernization, data centers, and defense applications.